Nielsen Michael F, Caumo Andrea, Chandramouli Visvanathan, Schumann William C, Cobelli Claudio, Landau Bernard R, Vilstrup Hendrik, Rizza Robert A, Schmitz Ole
Dept. of Surgical Gastroenterology L, Aarhus Kommunehospital, University of Aarhus, DK-8000 Aarhus C, Denmark.
Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E102-10. doi: 10.1152/ajpendo.00566.2002. Epub 2003 Sep 9.
Excess cortisol has been demonstrated to impair hepatic and extrahepatic insulin action. To determine whether glucose effectiveness and, in terms of endogenous glucose release (EGR), gluconeogenesis, also are altered by hypercortisolemia, eight healthy subjects were studied after overnight infusion with hydrocortisone or saline. Glucose effectiveness was assessed by a combined somatostatin and insulin infusion protocol to maintain insulin concentration at basal level in the presence of prandial glucose infusions. Despite elevated insulin concentrations (P < 0.05), hypercortisolemia resulted in higher glucose (P < 0.05) and free fatty acid concentrations (P < 0.05). Furthermore, basal insulin concentrations were higher during hydrocortisone than during saline infusion (P < 0.01), indicating the presence of steroid-induced insulin resistance. Postabsorptive glucose production (P = 0.64) and the fractional contribution of gluconeogenesis to EGR (P = 0.33) did not differ on the two study days. During the prandial glucose infusion, the integrated glycemic response above baseline was higher in the presence of hydrocortisone than during saline infusion (P < 0.05), implying a decrease in net glucose effectiveness (4.42 +/- 0.52 vs. 6.65 +/- 0.83 ml.kg-1.min-1; P < 0.05). To determine whether this defect is attributable to an impaired ability of glucose to suppress glucose production, to stimulate its own uptake, or both, glucose turnover and "hot" (labeled) indexes of glucose effectiveness (GE) were calculated. Hepatic GE was lower during cortisol than during saline infusion (2.39 +/- 0.24 vs. 3.82 +/- 0.51 ml.kg-1.min-1; P < 0.05), indicating a defect in the ability of glucose to restrain its own production. In addition, in the presence of excess cortisol, glucose disappearance was inappropriate for the prevailing glucose concentration, implying a decrease in glucose clearance (P < 0.05). The decrease in glucose clearance was confirmed by the higher increment in [3-3H]glucose during hydrocortisone than during saline infusion (P < 0.05), despite the administration of identical tracer infusion rates. In conclusion, short-term hypercortisolemia in healthy individuals with normal beta-cell function decreases insulin action but does not alter rates of EGR and gluconeogenesis. In addition, cortisol impairs the ability of glucose to suppress its own production, which due to accumulation of glucose in the glucose space results in impaired peripheral glucose clearance. These results suggest that cortisol excess impairs glucose tolerance by decreasing both insulin action and glucose effectiveness.
已有研究表明,皮质醇过量会损害肝脏及肝外组织的胰岛素作用。为了确定高皮质醇血症是否也会改变葡萄糖效能以及内源性葡萄糖释放(EGR)和糖异生情况,对8名健康受试者进行了研究,他们在夜间分别输注氢化可的松或生理盐水。通过联合使用生长抑素和胰岛素输注方案来评估葡萄糖效能,即在输注餐时葡萄糖的情况下将胰岛素浓度维持在基础水平。尽管胰岛素浓度升高(P < 0.05),但高皮质醇血症导致葡萄糖浓度(P < 0.05)和游离脂肪酸浓度升高(P < 0.05)。此外,氢化可的松输注期间的基础胰岛素浓度高于生理盐水输注期间(P < 0.01),表明存在类固醇诱导的胰岛素抵抗。在两个研究日,吸收后葡萄糖生成(P = 0.64)以及糖异生对EGR的贡献率(P = 0.33)并无差异。在输注餐时葡萄糖期间,氢化可的松存在时高于生理盐水输注时高于基线的综合血糖反应(P < 0.05),这意味着净葡萄糖效能降低(4.42±0.52 vs. 6.65±0.83 ml·kg⁻¹·min⁻¹;P < 0.05)。为了确定这种缺陷是由于葡萄糖抑制葡萄糖生成的能力受损、刺激自身摄取的能力受损还是两者皆有,计算了葡萄糖周转率和葡萄糖效能(GE)的“热”(标记)指标。氢化可的松输注期间的肝脏GE低于生理盐水输注期间(2.39±0.24 vs. 3.82±0.51 ml·kg⁻¹·min⁻¹;P < 0.05),表明葡萄糖抑制自身生成的能力存在缺陷。此外,在皮质醇过量的情况下,葡萄糖消失与当时的葡萄糖浓度不匹配,这意味着葡萄糖清除率降低(P < 0.05)。尽管给予相同的示踪剂输注速率,但氢化可的松输注期间[3 - ³H]葡萄糖的增量高于生理盐水输注期间(P < 0.05),这证实了葡萄糖清除率的降低。总之,在β细胞功能正常的健康个体中,短期高皮质醇血症会降低胰岛素作用,但不会改变EGR和糖异生速率。此外,皮质醇会损害葡萄糖抑制自身生成的能力,这由于葡萄糖在葡萄糖空间中的积累导致外周葡萄糖清除受损。这些结果表明,皮质醇过量通过降低胰岛素作用和葡萄糖效能损害葡萄糖耐量。